OBJECTIVES AND BACKGROUND: Activation of the immune system is well established in patients with chronic heart failure (CHF) and impaired left ventricular function. High levels of pro-inflammatory cytokines are associated with a poor prognosis. Chronic thromboembolic pulmonary hypertension (CTEPH) frequently leads to impaired right ventricular function. It is not known whether such patients display chronic immune activation as well. METHODS AND RESULTS: We studied 49 patients with CTEPH (50±2 years, right ventricular ejection fraction [RVEF] 29±2%, left ventricular ejection fraction [LVEF] 51±3%, mean±SEM) and compared their results with 17 patients with CHF (71±2 years, LVEF 23±1%) and 34 age-matched control subjects (age 57±2 years). We studied serum levels of tumor necrosis factor-α (TNFα), its soluble receptors 1 and 2 (sTNFR1 and 2), interleukin-10 (IL-10) and plasma N-terminal-pro-B-type natriuretic peptide (NT-proBNP). Serum TNFα was not different in CTEPH compared with CHF patients (p=0.67) but both their levels were significantly higher than in controls (both p<0.001). Similar results were obtained for sTNFR1, sTNFR2, and IL-10. Levels of NT-proBNP were not different in patients with CTEPH or CHF (p=0.54), but significantly higher than in control subjects (both p<0.001). There were significant correlations between RVEF as assessed by magnetic resonance imaging and sTNFR1, sTNFR2, IL-6, high sensitivity C-reactive protein, and NT-proBNP (all p<0.05) in patients with CTEPH. CONCLUSION: Similar levels of immune activation as reflected by high levels of pro-inflammatory cytokines are present in patients with isolated right ventricular dysfunction due to CTEPH and patients with CHF and left ventricular dysfunction.
OBJECTIVES AND BACKGROUND: Activation of the immune system is well established in patients with chronic heart failure (CHF) and impaired left ventricular function. High levels of pro-inflammatory cytokines are associated with a poor prognosis. Chronic thromboembolic pulmonary hypertension (CTEPH) frequently leads to impaired right ventricular function. It is not known whether such patients display chronic immune activation as well. METHODS AND RESULTS: We studied 49 patients with CTEPH (50±2 years, right ventricular ejection fraction [RVEF] 29±2%, left ventricular ejection fraction [LVEF] 51±3%, mean±SEM) and compared their results with 17 patients with CHF (71±2 years, LVEF 23±1%) and 34 age-matched control subjects (age 57±2 years). We studied serum levels of tumor necrosis factor-α (TNFα), its soluble receptors 1 and 2 (sTNFR1 and 2), interleukin-10 (IL-10) and plasma N-terminal-pro-B-type natriuretic peptide (NT-proBNP). Serum TNFα was not different in CTEPH compared with CHFpatients (p=0.67) but both their levels were significantly higher than in controls (both p<0.001). Similar results were obtained for sTNFR1, sTNFR2, and IL-10. Levels of NT-proBNP were not different in patients with CTEPH or CHF (p=0.54), but significantly higher than in control subjects (both p<0.001). There were significant correlations between RVEF as assessed by magnetic resonance imaging and sTNFR1, sTNFR2, IL-6, high sensitivity C-reactive protein, and NT-proBNP (all p<0.05) in patients with CTEPH. CONCLUSION: Similar levels of immune activation as reflected by high levels of pro-inflammatory cytokines are present in patients with isolated right ventricular dysfunction due to CTEPH and patients with CHF and left ventricular dysfunction.
Authors: Stephan von Haehling; Ewa A Jankowska; Dirk J van Veldhuisen; Piotr Ponikowski; Stefan D Anker Journal: Nat Rev Cardiol Date: 2015-07-21 Impact factor: 32.419
Authors: Guy Hagan; Mark Southwood; Carmen Treacy; Robert Mackenzie Ross; Elaine Soon; James Coulson; Karen Sheares; Nicholas Screaton; Joanna Pepke-Zaba; Nicholas W Morrell; James H F Rudd Journal: Pulm Circ Date: 2011 Oct-Dec Impact factor: 3.017
Authors: Song Gu; Pixiong Su; Jun Yan; Xitao Zhang; Xiangguang An; Jie Gao; Rui Xin; Yan Liu Journal: Int J Mol Med Date: 2013-12-10 Impact factor: 4.101
Authors: Bernhard Moser; Anna Megerle; Christine Bekos; Stefan Janik; Tamás Szerafin; Peter Birner; Ana-Iris Schiefer; Michael Mildner; Irene Lang; Nika Skoro-Sajer; Roela Sadushi-Kolici; Shahrokh Taghavi; Walter Klepetko; Hendrik Jan Ankersmit Journal: PLoS One Date: 2014-09-04 Impact factor: 3.240
Authors: Akylbek Sydykov; Argen Mamazhakypov; Aleksandar Petrovic; Djuro Kosanovic; Akpay S Sarybaev; Norbert Weissmann; Hossein A Ghofrani; Ralph T Schermuly Journal: Front Physiol Date: 2018-05-23 Impact factor: 4.566
Authors: Manuel Jonas Richter; Katrin Milger; Sarah Haase; Natascha Sommer; Khodr Tello; Werner Seeger; Eckhard Mayer; Christoph Benjamin Wiedenroth; Friedrich Grimminger; Wolfgang George; Hossein Ardeschir Ghofrani; Stefan Guth; Henning Gall Journal: PLoS One Date: 2016-03-31 Impact factor: 3.240
Authors: S F Fonseca; V A Mendonça; M C Teles; V G C Ribeiro; R Tossige-Gomes; C D C Neves; E Rocha-Vieira; L H R Leite; D D Soares; C C Coimbra; A C R Lacerda Journal: Braz J Med Biol Res Date: 2016-02-02 Impact factor: 2.590